These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3073074)

  • 21. Glomerular dysfunction in diabetic nephropathy.
    Zucchelli P; Zuccalà A; Sturani A
    Postgrad Med J; 1988; 64 Suppl 3():22-30; discussion 48-9. PubMed ID: 3074295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomic challenges in the management of diabetic nephropathy.
    Rodby RA
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S6-11. PubMed ID: 15369419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic nephropathy: from micro- to macroalbuminuria.
    Deferrari G; Repetto M; Calvi C; Ciabattoni M; Rossi C; Robaudo C
    Nephrol Dial Transplant; 1998; 13 Suppl 8():11-5. PubMed ID: 9870419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiologic analysis of diabetic patients on chronic dialysis.
    Sunagawa H; Iseki K; Nishime K; Uehara H; Toma S; Kinjo K; Fukiyama K
    Nephron; 1996; 74(2):361-6. PubMed ID: 8893156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Premature cell ageing and evolution of diabetic nephropathy.
    Morocutti A; Earle KA; Rodemann HP; Viberti GC
    Diabetologia; 1997 Feb; 40(2):244-6. PubMed ID: 9049488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The renal hemodynamic basis of diabetic nephropathy.
    O'Bryan GT; Hostetter TH
    Semin Nephrol; 1997 Mar; 17(2):93-100. PubMed ID: 9148381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Microalbuminuria and diabetic nephropathy. Detection and correlation with other degenerative complications].
    Thivolet C; Ayzac L; Simonet C; Rebattu B; Bernard P; Tourniaire J
    Presse Med; 1990 Jun; 19(23):1075-80. PubMed ID: 2141408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The health care costs of diabetic nephropathy in the United States and the United Kingdom.
    Gordois A; Scuffham P; Shearer A; Oglesby A
    J Diabetes Complications; 2004; 18(1):18-26. PubMed ID: 15019595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy.
    Bretzel RG
    Am J Hypertens; 1997 Sep; 10(9 Pt 2):208S-217S. PubMed ID: 9324124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased prevalence of proliferative retinopathy and cardiovascular autonomic dysfunction in IDDM patients with proteinuria.
    Zander E; Seidlein I; Herfurth S; Heinke P; Chlup R; Badendick K; Strese J; Zander G; Schulz B
    Exp Clin Endocrinol; 1992; 99(2):102-7. PubMed ID: 1639116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diabetic nephropathy and prevention of diabetic nephropathy caused chronic renal insufficiency].
    Jakić M; Jakić M; Zibar L; Mihaljević D; Stipanić S; Teskera T
    Lijec Vjesn; 2009; 131(7-8):218-25. PubMed ID: 19769285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.
    Garattini L; Brunetti M; Salvioni F; Barosi M
    Pharmacoeconomics; 1997 Jul; 12(1):67-75. PubMed ID: 10169388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic nephropathy--prevention and treatment.
    Agarwal DK
    J Indian Med Assoc; 2002 Mar; 100(3):158-60, 162-3. PubMed ID: 12408275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in understanding mechanisms and natural history of diabetic renal disease.
    Viberti G
    Diabetes Care; 1988; 11 Suppl 1():3-9. PubMed ID: 3069389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
    Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early diabetic nephropathy: assessment and potential therapeutic interventions.
    Rosenstock J; Raskin P
    Diabetes Care; 1986; 9(5):529-45. PubMed ID: 3533477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic nephropathy: natural course, survivorship and therapy.
    McCrary RF; Pitts TO; Puschett JB
    Am J Nephrol; 1981; 1(3-4):206-18. PubMed ID: 6758579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.